Publications by the researcher in collaboration with Vicente Soriano Vázquez (58)

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  3. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  4. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  3. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2012

  1. Endothelial dysfunction in HIV infection - The role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages

    AIDS Reviews, Vol. 14, Núm. 4, pp. 223-230

2011

  1. Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance

    Journal of Viral Hepatitis, Vol. 18, Núm. 1, pp. 11-16

2010

  1. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 3, pp. 543-547

  2. Management of metabolic complications and cardiovascular risk in HIV-infected patients

    AIDS Reviews, Vol. 12, Núm. 4, pp. 231-241

  3. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  4. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

  5. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 8, pp. 1567-1569

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

  2. Differences in lopinavir plasma concentrations comparing Kaletra® film coated tablets and soft gelatine capsules that result in various lipid abnormalities

    Drug Metabolism Letters, Vol. 3, Núm. 2, pp. 67-69

  3. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 398-410